Brief: Nuvectis Pharma Provides Final Clinical Data Update From The NXP800 Phase 1B Study In Ovarian Cancer And Reports Completion Of The NXP900 Phase 1A Dose Escalation Study
31/07/2025 13:49
July 31 (Reuters) - Nuvectis Pharma Inc NVCT.O: NUVECTIS PHARMA PROVIDES FINAL CLINICAL DATA UPDATE FROM THE NXP800 PHASE 1B STUDY IN OVARIAN CANCER AND REPORTS COMPLETION OF THE NXP900 PHASE 1A DOSE ESCALATION STUDY NUVECTIS PHARMA INC - NXP800 PHASE 1B STUDY SHOWS 2 PARTIAL RESPONSES, 3 STABLE DISEASES NUVECTIS PHARMA INC - NXP900 COMPLETES PHASE 1A STUDY, PHASE 1B TO START SOON Source text: ID:nGNX9Drgy2 Further company coverage: NVCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin